Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 7Phase 1/2 5Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Syndrome, Transient 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Chromosome 5q Deletion Syndrome 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 182Docetaxel 166Gemcitabine 165Oxaliplatin 162Carboplatin 160Paclitaxel 152Leucovorin 122Drug Therapy 118Dexamethasone 118Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 56Neoadjuvant Therapy 53Lenalidomide 52Letrozole 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

Phase 3 Completed
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡